- Government-advocacy-industry collaboration is national program to raise
awareness of emphysema and chronic bronchitis (COPD) -
NAPA, Calif., Nov. 28 /PRNewswire/ -- In recognition of November as
National COPD Awareness Month, Dey, L.P., a subsidiary of Mylan Inc. (NYSE:
MYL), has entered into a partnership with the COPD Foundation in support of
the National Heart, Lung and Blood Institute (NHLBI) to raise public
awareness of Chronic Obstructive Pulmonary Disease (COPD), also known as
emphysema or chronic bronchitis. Through an unrestricted educational grant
to the COPD Foundation, Dey, L.P. is supporting the COPD Learn More Breathe
Better campaign, an ongoing initiative to educate the public about COPD and
its treatment, and to urge screening and early detection of the disease.
According to the NHLBI's COPD Learn More Breathe Better campaign, COPD
is the fourth leading cause of death in the U.S. after heart disease,
cancer, and stroke. Approximately 12 million Americans are being treated
for the disease, and it is estimated that at least another 12 million are
unaware that they suffer from COPD. A simple screening test called
spirometry can identify those affected by COPD and enable them to start
receiving treatment. The COPD Learn More Breathe Better campaign targets
people over the age of 45, particularly current or former smokers or people
at risk for a genetic predisposition to COPD or environmental exposures.
"COPD is a hidden epidemic in this country, and National COPD Awareness
Month is critically important as an opportunity to combat the public health
crisis of this disease," said John W. Walsh, President of the COPD
Foundation and President and CEO of The Alpha-1 Foundation. "On behalf of
the COPD Foundation, I salute Dey, L.P. for becoming the first
pharmaceutical company to provide support for this national public
awareness campaign. The company's commitment to patients and their
caregivers is reflected not only in its support of the COPD Learn More
Breathe Better campaign, but also in its newly created educational resource
kit for COPD caregivers. The COPD Foundation is delighted now to be able to
offer these unique, free resource kits through our COPD Call Center."
"We are proud to join the COPD Foundation in support of the NHLBI's
effort to increase public awareness of COPD," said Carolyn Myers, Ph.D.,
President of Dey, L.P. "As a U.S. leader in nebulized respiratory
medications, we have a strong commitment to helping patients understand
COPD and receive appropriate treatment. Through this collaboration with the
COPD Foundation in support of the NHLBI, Dey will contribute to the
campaign's consumer education events as well as to its distribution of
educational materials to physicians and the general public."
Caring for Someone with Emphysema or Chronic Bronchitis, Dey's new
educational resource kit for COPD caregivers, provides disease information,
an overview of various COPD treatment options, and practical lifestyle tips
and other suggestions on ways to care for someone living with COPD. Free
copies of this COPD caregiver kit may be requested through the COPD
Foundation Call Center at 1-866-316-COPD.
About COPD
COPD refers to a number of chronic lung disorders in which the airways
to the lungs become narrowed and breathing becomes increasingly difficult.
The most common forms of COPD are chronic bronchitis and emphysema, and
many patients suffer from a combination of the two diseases.
COPD is not well understood or recognized -- most Americans have not
heard of it, not even those who may be living with the condition. The most
common cause of COPD is cigarette smoking, which is responsible for an
estimated 80 to 90 percent of COPD cases. Estimates of the total incidence
of COPD in America range from 24 to 30 million.
About Dey, L.P.
Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty
pharmaceutical company focused on the development, manufacturing and
marketing of prescription drug products for the treatment of respiratory
diseases, respiratory-related allergies, and emergency care medicine. As
the U.S. leader in sales of nebulized respiratory medication, Dey, L.P.
puts patients first through its development of innovative and affordable
therapies. The Web sites for Dey, L.P. include http://www.dey.com,
http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.duoneb.com,
http://www.epipen.com and http://www.perforomist.com.
About Mylan
Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a
global commercial footprint through operations in more than 90 countries.
Through its controlling interest in Matrix Laboratories Limited, Mylan has
direct access to one of the largest active pharmaceutical ingredient (API)
manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and diversified
opportunities in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit http://www.mylan.com
Media contacts: Dey, L.P. Media Line
1-800-755-5560 ext. 8363
or
Harriet Ullman
Feinstein Kean Healthcare
617-761-6776
hullman@fkhealth.com
SOURCE Dey, L.P.
 back to top
Related links:
http://www.dey.com
http://www.mylan.com
CONTACT:
Dey, L.P. Media Line, +1-800-755-5560 ext.
8363; Harriet Ullman of Feinstein Kean Healthcare,
+1-617-761-6776, hullman@fkhealth.com
|
